Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Athira Pharma Inc (NASDAQ: ATHA) closed at $0.64 in the last session, down -4.25% from day before closing price of $0.67. In other words, the price has decreased by -$4.25 from its previous closing price. On the day, 0.78 million shares were traded. ATHA stock price reached its highest trading level at $0.6799 during the session, while it also had its lowest trading level at $0.6156.
Ratios:
We take a closer look at ATHA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.95 and its Current Ratio is at 2.95. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on September 19, 2024, Downgraded its rating to Neutral and sets its target price to $0.50 from $5 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 05 ’24 when Mark James Litton bought 5,032 shares for $0.00 per share.
Gengos Andrew sold 1,272 shares of ATHA for $720 on Sep 05 ’24. The CFO and Chief Business Officer now owns 97,532 shares after completing the transaction at $0.57 per share. On Sep 05 ’24, another insider, Lenington Rachel, who serves as the COO and CDO of the company, sold 2,525 shares for $0.57 each. As a result, the insider received 1,429 and left with 20,870 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATHA now has a Market Capitalization of 24810096 and an Enterprise Value of -61532468.
Stock Price History:
The Beta on a monthly basis for ATHA is 2.92, which has changed by -0.5472973 over the last 52 weeks, in comparison to a change of 0.2936039 over the same period for the S&P500. Over the past 52 weeks, ATHA has reached a high of $4.30, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is 25.04%, while the 200-Day Moving Average is calculated to be -70.90%.
Shares Statistics:
According to the various share statistics, ATHA traded on average about 5.14M shares per day over the past 3-months and 3360170 shares per day over the past 10 days. A total of 38.17M shares are outstanding, with a floating share count of 35.55M. Insiders hold about 8.08% of the company’s shares, while institutions hold 47.72% stake in the company. Shares short for ATHA as of 1728950400 were 1557749 with a Short Ratio of 0.30, compared to 1726185600 on 1645197. Therefore, it implies a Short% of Shares Outstanding of 1557749 and a Short% of Float of 5.7600003.
Earnings Estimates
A detailed examination of Athira Pharma Inc (ATHA) is currently in progress, with 5.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.2 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$2.35 and -$2.66 for the fiscal current year, implying an average EPS of -$2.53. EPS for the following year is -$1.48, with 4.0 analysts recommending between -$0.66 and -$3.27.
